New antibody shows promise for painful skin condition
NCT ID NCT04856930
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a drug called imsidolimab (ANB019) in 149 people with hidradenitis suppurativa, a chronic skin condition causing painful abscesses and nodules. Participants received either the drug or a placebo to see if it could reduce the number of inflamed lesions. The study is complete, and results will show whether this antibody approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imsidolimab (ANB019), a lab-made antibody
- What this could lead to
- If it works, this could point toward a new treatment option for hidradenitis suppurativa, reducing painful abscesses and nodules.
- What could go wrong
- This is a mid-stage trial with only 149 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 10-101
Fort Gratiot, Michigan, 48059, United States
-
Site 10-102
Sacramento, California, 95817, United States
-
Site 10-103
Portsmouth, New Hampshire, 03801, United States
-
Site 10-104
Fountain Valley, California, 92708, United States
-
Site 10-105
Norfolk, Virginia, 23502, United States
-
Site 10-106
Spokane, Washington, 99202, United States
-
Site 10-107
Largo, Florida, 33770, United States
-
Site 10-108
Birmingham, Alabama, 35224, United States
-
Site 10-109
Coral Gables, Florida, 33134, United States
-
Site 10-110
Sandy Springs, Georgia, 30328, United States
-
Site 10-111
Tampa, Florida, 33607, United States
-
Site 10-112
Pflugerville, Texas, 78660, United States
-
Site 10-113
Greenville, South Carolina, 29615, United States
-
Site 10-115
Warwick, Rhode Island, 02886, United States
-
Site 10-117
San Antonio, Texas, 78213, United States
-
Site 10-118
Houston, Texas, 77056, United States
-
Site 10-119
Northridge, California, 91324, United States
-
Site 11-101
Saint-Jérôme, Quebec, J7Z 7E2, Canada
-
Site 11-102
Markham, Ontario, L3P 1X3, Canada
-
Site 11-103
Cobourg, Ontario, K9A 0Z4, Canada
-
Site 11-105
Québec, Quebec, G1N 4V3, Canada
-
Site 11-106
Calgary, Alberta, T2J7E1, Canada
-
Site 30-103
Ossy, Silesian Voivodeship, 42-624, Poland
-
Site 30-104
Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
-
Site 30-106
Olsztyn, 10-229, Poland
-
Site 30-107
Krakow, Malopolska, 30-074, Poland
-
Site 30-108
Katowice, Silesian Voivodeship, 40-611, Poland
-
Site 30-109
Lodz, 90-265, Poland
-
Site 59-102
Tbilisi, 112, Georgia
-
Site 59-103
Tbilisi, 160, Georgia
-
Site 59-104
Tbilisi, 159, Georgia
-
Site 59-105
Tbilisi, 160, Georgia
-
Site 59-106
Batumi, 6000, Georgia
-
Site 59-107
Tbilisi, 162, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition
- New pill for painful skin disease enters first human tests